On April 23, Biomet
- Revenues growth was quite modest, checking in under 5%.
- Net profit was lower because of declining margins.
- Biomet is in the midst of cleaning up a stock options grant mess dating all the way back to 1996.
- Biomet will be taken private by a private equity group pending shareholder approval.
(Figures in millions, except per-share data.)
Income Statement Highlights
|
Q3 2007 |
Q3 2006 |
Change |
|
|---|---|---|---|
|
Sales |
$529.5 |
$506.3 |
4.6% |
|
Net Profit |
$84.4 |
$106.1 |
(20.4%) |
|
EPS |
$245.4 |
$247.8 |
(1.0%) |
|
Diluted Shares |
0.3 |
0.4 |
(20.9%) |
Get back to basics with the income statement.
Margin Checkup
|
Q3 2007 |
Q3 2006 |
Change* |
|
|---|---|---|---|
|
Gross Margin |
69.1% |
71.7% |
(2.7) |
|
Operating Margin |
23.4% |
31.0% |
(7.6) |
|
Net Margin |
15.9% |
21.0% |
(5.0) |
Margins are the earnings engine.
Balance Sheet Highlights
|
Assets |
Q3 2007 |
Q3 2006 |
Change |
|---|---|---|---|
|
Cash + ST Invest. |
$134.0 |
$110.6 |
21.1% |
|
Accounts Rec. |
$544.8 |
$498.8 |
9.2% |
|
Inventory |
$550.7 |
$523.3 |
5.2% |
|
Liabilities |
Q3 2007 |
Q3 2006 |
Change |
|---|---|---|---|
|
Accounts Payable |
$52.3 |
$60.2 |
(13.1%) |
The balance sheet reflects the company's health.
Cash Flow Highlights
|
YTD 2007 |
YTD 2006 |
Change |
|
|---|---|---|---|
|
Cash From Ops. |
$296.4 |
$277.9 |
6.6% |
|
Capital Expenditures |
$89.0 |
$75.3 |
18.3% |
|
Free Cash Flow |
$207.4 |
$202.7 |
2.3% |
Free cash flow is a Fool's best friend.
Related Foolishness:
- Only One Bone to Pick With Stryker
- Turnaround Time for Biotech?
- Acquisitions Mark Pharmaceutical Industry
Fool by Numbers is designed to give you the raw earnings information in a timely fashion, putting all the numbers you need in one easy-to-read place. But at The Motley Fool, we believe numbers tell only part of the story, so check Fool.com for more of our in-depth discussion of what the numbers mean. This data has been provided by Netscribes. To provide feedback on this article, please click on the "feedback" button below.
